Factors Associated With Resource Utilization and Coronary Artery Dilation in Refractory Kawasaki Disease (from the Pediatric Health Information System Database) Jennifer Y. Lo, MD, L. LuAnn Minich, MD, Lloyd Y. Tani, MD, Jacob Wilkes, BS, Qian Ding, MStat, Shaji C. Menon, MD American Journal of Cardiology Volume 118, Issue 11, Pages 1636-1640 (December 2016) DOI: 10.1016/j.amjcard.2016.08.039 Copyright © 2016 Elsevier Inc. Terms and Conditions
Figure 1 IVIG and immunomodulator therapies used in the refractory KD group. American Journal of Cardiology 2016 118, 1636-1640DOI: (10.1016/j.amjcard.2016.08.039) Copyright © 2016 Elsevier Inc. Terms and Conditions
Figure 2 (A) Immunomodulators that were prescribed for refractory KD. (B) Antithrombotics, in addition to aspirin, that were prescribed for refractory KD. American Journal of Cardiology 2016 118, 1636-1640DOI: (10.1016/j.amjcard.2016.08.039) Copyright © 2016 Elsevier Inc. Terms and Conditions
Figure 3 Forest plots showing multivariate regression analyses of factors associated with (A) antithrombotic therapy, (B) charges, and (C) LOS in refractory KD. American Journal of Cardiology 2016 118, 1636-1640DOI: (10.1016/j.amjcard.2016.08.039) Copyright © 2016 Elsevier Inc. Terms and Conditions